Tsapekos, Dimosthenis
Strawbridge, Rebecca
Cella, Matteo
Goldsmith, Kimberley
Kalfas, Michail
Taylor, Rosie H.
Swidzinski, Samuel
Marwaha, Steven
Grey, Libby
Newton, Elizabeth
Shackleton, Julie
Harrison, Paul J.
Browning, Michael
Harmer, Catherine
Hartland, Hannah
Cousins, David
Barton, Stephen
Wykes, Til
Young, Allan H.
Funding for this research was provided by:
National Institute for Health and Care Research (NIHR132619, NIHR132619, NIHR132619, NIHR132619, NIHR132619, NIHR132619, NIHR132619, NIHR132619, NIHR132619, NIHR132619, NIHR132619, NIHR132619, NIHR132619, NIHR132619, NIHR132619, NIHR132619, NIHR132619, NIHR132619, NIHR132619)
Article History
Received: 17 October 2023
Accepted: 30 October 2023
First Online: 15 November 2023
Declarations
:
: Ethical approval has been granted by the London – Bromley Research Ethics Committee in Spring 2022 (REC reference number 22/LO/0210). The trial will be conducted in compliance with the principles of the Declaration of Helsinki (1996), the principles of GCP, and in accordance with all applicable regulatory requirements including but not limited to the Research Governance Framework and the Mental Capacity Act 2005. All participants provide informed written consent prior their participation.
: Not applicable (NA).
: TW was involved in the development of CIRCuiTS cognitive remediation programme. However, they are not involved in study assessment procedures, data entry, or analysis. Other authors declare that they have no competing interests for this study.During this study, AY (trial CI) has been the editor of Journal of Psychopharmacology and Deputy Editor for BJPsych Open. He has conducted paid lectures and advisory boards for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, COMPASS, Sage and Novartis and Neurocentrx. He is the Principal Investigator in the Restore-Life VNS registry study funded by LivaNova, ESKETINTRD3004: "An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression", "The Effects of Psilocybin on Cognitive Function in Healthy Participants" and "The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD)". He is UK chief Investigator for Compass COMP006 & COMP007 studies, Novartis MDD study MIJ821A12201. He has received grant funding (past and present) from: NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK). Janssen (UK), EU Horizon 2020. He has no shareholdings in pharmaceutical companies.